Johnson & Johnson (NYSE:JNJ) is up 0.5% at $255.03 this morning, attempting to pivot higher and shed its early pre-market losses. The pharma company posted an earnings per share of $2.84 on revenue of $25.31 billion, citing success within its medicine unit. JNJ was brushing off the report earlier, but now sits modestly higher as it struggles for direction.
JNJ sports a 23.5% gain for 2026, though the shares have pulled back slightly from their July 7 record peak of $269.43. Today's whipsaw price action is testing the $250 floor, with the ascending 20-day moving average stepping up as support.
While analysts have yet to chime in on the event, there was a heavy bullish presence heading into today. Currently 16 of the 25 brokerages in coverage sport a "buy" or "strong buy" recommendation, while the average 12-month price target of $258.59 is a slight premium to current levels.
Its also worth noting JNJ's Schaeffer's Volatility Scorecards (SVS) reading of 79 out of 100. This suggests the stock has realized higher volatility than its options have priced in over the past 12 months.
